Adaptive Biotechnologies annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies's operating margin was −20.62% for fiscal 2025.
View full Adaptive Biotechnologies company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −20.62% | +70.21 pp |
| 2024 | 2024-12-31 | −90.83% | +42.50 pp |
| 2023 | 2023-12-31 | −133.33% | −25.30 pp |
| 2022 | 2022-12-31 | −108.03% | +27.36 pp |
| 2021 | 2021-12-31 | −135.39% | +19.94 pp |
| 2020 | 2020-12-31 | −155.33% | −63.18 pp |
| 2019 | 2019-12-31 | −92.15% | −2.76 pp |
| 2018 | 2018-12-31 | −89.39% | +26.29 pp |
| 2017 | 2017-12-31 | −115.68% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −22.04% | +20.48 pp |
| Q1 2026 | 2026-03-31 | −27.10% | +29.35 pp |
| Q4 2025 | 2025-12-31 | −17.82% | +53.48 pp |
| Q3 2025 | 2025-09-30 | 10.95% | +81.22 pp |
| Q2 2025 | 2025-06-30 | −42.52% | +67.04 pp |
| Q1 2025 | 2025-03-31 | −56.45% | +60.00 pp |
| Q4 2024 | 2024-12-31 | −71.30% | +83.93 pp |
| Q3 2024 | 2024-09-30 | −70.27% | +64.11 pp |
| Q2 2024 | 2024-06-30 | −109.56% | −11.82 pp |
| Q1 2024 | 2024-03-31 | −116.45% | +35.47 pp |
| Q4 2023 | 2023-12-31 | −155.22% | −84.23 pp |
| Q3 2023 | 2023-09-30 | −134.38% | −39.40 pp |
| Q2 2023 | 2023-06-30 | −97.74% | +22.52 pp |
| Q1 2023 | 2023-03-31 | −151.92% | +11.38 pp |
| Q4 2022 | 2022-12-31 | −70.99% | +91.40 pp |
| Q3 2022 | 2022-09-30 | −94.98% | +47.73 pp |
| Q2 2022 | 2022-06-30 | −120.25% | +8.99 pp |
| Q1 2022 | 2022-03-31 | −163.30% | −55.92 pp |
| Q4 2021 | 2021-12-31 | −162.39% | −15.83 pp |
| Q3 2021 | 2021-09-30 | −142.71% | −1.84 pp |
| Q2 2021 | 2021-06-30 | −129.24% | +46.61 pp |
| Q1 2021 | 2021-03-31 | −107.38% | +58.18 pp |
| Q4 2020 | 2020-12-31 | −146.56% | −46.65 pp |
| Q3 2020 | 2020-09-30 | −140.88% | −71.60 pp |
| Q2 2020 | 2020-06-30 | −175.86% | −103.11 pp |
| Q1 2020 | 2020-03-31 | −165.57% | −7.31 pp |
| Q4 2019 | 2019-12-31 | −99.91% | −46.61 pp |
| Q3 2019 | 2019-09-30 | −69.28% | +45.80 pp |
| Q2 2019 | 2019-06-30 | −72.75% | — |
| Q1 2019 | 2019-03-31 | −158.26% | — |
| Q3 2018 | 2018-09-30 | −53.30% | — |
| Q2 2018 | 2018-06-30 | −115.08% | — |
Over the last five reported fiscal years, Adaptive Biotechnologies's operating margin increased from −155.33% to −20.62%, a change of +134.71 percentage points. The latest reported quarter, Q2 2026, shows −22.04%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptive Biotechnologies filings at SEC.gov ↗